A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer
Bogang Wu(George Washington University), Leif W. Ellisen(Harvard University), Rachel O. Abelman(Massachusetts General Hospital), David T. Ting(Massachusetts General Hospital), Elena Bitman(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Sheng Sun(Harvard University), Win Thant(Massachusetts General Hospital), Jie Liu(Shenyang Pharmaceutical University), Ting Liu(Harvard University), Katherine Xu(Harvard University), Steven J. Isakoff(Harvard University), Aditya Bardia(Harvard University), Eleftherios I. Paschalis(Massachusetts Eye and Ear Infirmary)
Cited by 5
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k